RFPs: Mito Foundation’s Incubator Grant Program

The Mito Foundation is accepting applications for its Incubator Grant Program, offering up to A$25,000 for innovative, early-stage research projects focused on primary mitochondrial disease. Grants support projects with strong potential for health, social impact, clinical capacity building, and economic outcomes, with funding for 12-month initiatives starting between July and October 2026. Applications close 13 March 2026, with outcomes announced in May 2026.

Program Overview

The Mito Foundation Incubator Grant Program provides targeted funding to novel research projects that benefit individuals affected by primary mitochondrial disease. The program emphasizes:

• Early-stage research rather than established programs

• Novelty and feasibility of proposed projects

• Clear impact and benefit for the mito community

Grants are charitable contributions, designed to accelerate research, inform decision-making, and strengthen the overall mito research ecosystem.

Key Focus Areas

Funding is intended for projects that contribute to:

• Health outcomes for individuals with primary mitochondrial disease

• Knowledge generation and dissemination in the mito field

• Social impact and community engagement

• Workforce research and clinical capacity building

• Economic outcomes related to mito care and research

Who is Eligible?

Eligible applicants include:

• Researchers based in Australia or overseas

• Projects must be centred on primary mitochondrial disease

• Early-stage research teams demonstrating novel approaches and feasibility

Applicants may partner with other organizations, though co-funding is optional. Projects are evaluated by the Scientific and Medical Advisory Panel and approved by the Mito Foundation Board of Directors.

Funding and Project Duration

• Maximum grant: A$25,000

• Project duration: up to 12 months

• Funding may not be used for on-costs, infrastructure, or indirect expenses

• Co-funding encouraged but not mandatory

How to Apply / Application Process

1. Prepare Proposal

   • Include project objectives, methodology, expected impact, and relevance to the mito community

   • Highlight novelty, feasibility, and potential outcomes

2. Submit Application

   • Complete the prescribed application template

   • Submit before 13 March 2026

3. Review Process

   • Expert peer review by the Scientific and Medical Advisory Panel

   • Recommendations forwarded to the Board of Directors for final approval

   • Foundation reserves the right not to fund any applications in a given year

4. Notification and Project Start

   • Outcomes announced: May 2026

   • Successful projects commence: July–October 2026

Assessment Criteria

Applications are evaluated based on:

1. Impact and benefit to the mito community

2. Novelty and innovation of the research

3. Methodological quality and feasibility

4. Track record and environment of the research team

5. Overall value for money

Reporting and Compliance

All successful applicants must comply with:

• Reporting obligations outlined in the funding agreement

• Timely submission of progress and final reports

Tips for Applicants

• Clearly articulate community benefit and expected outcomes

• Emphasize innovation and feasibility

• Provide strong evidence of the research team’s capability

• Ensure budget aligns with eligible expenses

Frequently Asked Questions (FAQ)

1. Who can apply?
   Australian and overseas researchers with projects focused on primary mitochondrial disease.

2. What is the maximum funding amount?
   A$25,000 per project for up to 12 months.

3. Can the funding be used for infrastructure or on-costs?
   No, grants cannot be used for indirect costs, infrastructure, or on-costs.

4. Is co-funding required?
   No, but co-funding from another organization is encouraged.

5. When is the application deadline?
   13 March 2026.

6. When will outcomes be announced?
   May 2026, with project commencement between July and October 2026.

7. How are applications evaluated?
   By the Scientific and Medical Advisory Panel, then approved by the Mito Foundation Board based on impact, innovation, feasibility, track record, and value for money.

Conclusion

The Mito Foundation Incubator Grant Program 2026 is a unique opportunity for researchers to conduct innovative, high-impact studies on primary mitochondrial disease. By supporting early-stage projects, the Foundation aims to advance health outcomes, build clinical capacity, and strengthen the mito research ecosystem, ultimately benefiting individuals and communities affected by this condition.